The nk1 fragment of hepatocyte growth factor/scatter factor (hgf/sf) and variants thereof, and their use
CA 2440775 C · Owner: Lietha, Daniel · Inventors: Gherardi, Ermanno; Blundell, Thomas Leon; Chirgadze, Dimitry Yurievich
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 29, 2002 and granted February 26, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 29, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 29, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.